Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD …
6516 Background: Monalizumab is a first-in-class immune checkpoint inhibitor targeting
Natural Killer Group 2A (NKG2A), which is expressed on subsets of Natural Killer (NK), gd T …
Natural Killer Group 2A (NKG2A), which is expressed on subsets of Natural Killer (NK), gd T …
[HTML][HTML] Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with …
RB Cohen, G Lefebvre, MR Posner, JR Bauman… - Annals of …, 2019 - Elsevier
Background Monalizumab is a first in class immune checkpoint inhibitor targeting Natural
Killer Group 2A (NKG2A), which is expressed as a heterodimer with CD94 on subsets of …
Killer Group 2A (NKG2A), which is expressed as a heterodimer with CD94 on subsets of …
Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head …
J Fayette, G Lefebvre, MR Posner… - Annals of …, 2018 - annalsofoncology.org
Background: Monalizumab (Mona) is an immune checkpoint inhibitor targeting NKG2A
receptors expressed on tumor-infiltrating CD8 T and Natural Killer (NK cells). The NKG2A …
receptors expressed on tumor-infiltrating CD8 T and Natural Killer (NK cells). The NKG2A …
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A …
DA Colevas, K Misiukiewicz, AT Pearson… - Annals of …, 2021 - annalsofoncology.org
Background Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group
2A (NKG2A), expressed on subsets of Natural Killer (NK) and tumor-infiltrating CD8+ T cells …
2A (NKG2A), expressed on subsets of Natural Killer (NK) and tumor-infiltrating CD8+ T cells …
An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck …
AG Sacco, R Chen, D Ghosh, DJL Wong, FP Worden… - 2019 - ascopubs.org
6033 Background: Pembrolizumab (a humanized monoclonal antibody blocking
programmed death receptor-1 [PD-1]), and cetuximab (a chimeric monoclonal antibody …
programmed death receptor-1 [PD-1]), and cetuximab (a chimeric monoclonal antibody …
[HTML][HTML] A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG …
R Galot, C Le Tourneau, E Saada-Bouzid… - European Journal of …, 2021 - Elsevier
Purpose Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055
R Haddad, T Seiwert, DG Pfister, F Worden… - Annals of …, 2016 - annalsofoncology.org
Background There are few treatment options in recurrent/metastatic (R/M) HNSCC after
progression on platinum and cetuximab, and their efficacy is disappointing. During …
progression on platinum and cetuximab, and their efficacy is disappointing. During …
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised …
AG Sacco, R Chen, FP Worden, DJL Wong… - The Lancet …, 2021 - thelancet.com
Summary Background Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are
active as single agents and in combination with cytotoxic chemotherapy for recurrent or …
active as single agents and in combination with cytotoxic chemotherapy for recurrent or …
854O INTERLINK-1: Phase III study of cetuximab (CTX)±monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M …
J Fayette, LFL Licitra, KJ Harrington… - Annals of …, 2023 - annalsofoncology.org
Background First-line (1L) treatment for R/M HNSCC includes ICI+/-CT or CT+ CTX.
Treatment after 1L failure is not clearly defined. Preliminary data suggest M (anti-NKG2A)+ …
Treatment after 1L failure is not clearly defined. Preliminary data suggest M (anti-NKG2A)+ …
First-line pembrolizumab±chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
S Takahashi, N Oridate, K Tanaka, Y Shimizu… - International Journal of …, 2022 - Springer
Background Here, we report the results of the Japanese subgroup of the phase 3 KEYNOTE-
048 study of pembrolizumab alone, pembrolizumab plus platinum and 5-fluorouracil …
048 study of pembrolizumab alone, pembrolizumab plus platinum and 5-fluorouracil …